Oscar Health (NYSE:OSCR) Issues Quarterly Earnings Results

Oscar Health (NYSE:OSCR) issued its earnings results on Wednesday. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96, FiscalAI reports. The company had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.90 billion. Oscar Health had a negative net margin of 3.79% and a negative return on equity of 39.35%. The firm’s quarterly revenue was up 52.6% compared to the same quarter last year. During the same period last year, the company posted $0.92 earnings per share.

Here are the key takeaways from Oscar Health’s conference call:

• Oscar reported a strong Q1 with $4.6B revenue (+53% YoY), earnings from operations of $704M, net income of $679M and adjusted EBITDA of $727M, and management reaffirmed full‑year 2026 guidance.
• Membership accelerated to 3.2 million (56% YoY), driven by above‑market open enrollment growth and solid retention, supporting scale and revenue upside.
• SG&A efficiency improved to a company‑low 15.2% of revenue, credited to disciplined cost management and expanding AI/tech use cases that management says will further lower per‑member costs.
• Risk adjustment remains a key swing factor: Q1 RA ran ~24% (seasonal/claims dynamics), above the company’s full‑year target of ~20%, and management cautioned RA and market morbidity uncertainty could materially affect 2026 EBITDA until further Wakely/claims data arrive.
• Balance sheet and capital position are strong with $8.1B cash & investments and ~$1.7B statutory surplus (including ~$809M excess), giving flexibility to fund growth and absorb volatility.

Oscar Health Trading Up 11.0%

Shares of Oscar Health stock traded up $1.98 during trading hours on Wednesday, reaching $19.92. 18,840,597 shares of the company’s stock were exchanged, compared to its average volume of 7,699,831. Oscar Health has a 52-week low of $10.69 and a 52-week high of $23.80. The company has a fifty day moving average of $14.11 and a 200-day moving average of $15.28. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $5.93 billion, a price-to-earnings ratio of -11.45 and a beta of 2.34.

Insiders Place Their Bets

In other Oscar Health news, CEO Mark T. Bertolini bought 1,000,000 shares of Oscar Health stock in a transaction that occurred on Monday, April 6th. The shares were purchased at an average cost of $11.92 per share, for a total transaction of $11,920,000.00. Following the completion of the transaction, the chief executive officer owned 10,196,876 shares of the company’s stock, valued at $121,546,761.92. This represents a 10.87% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 25.11% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Thrive Capital Management LLC boosted its position in shares of Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after acquiring an additional 1,588,395 shares during the last quarter. Baird Financial Group Inc. acquired a new position in Oscar Health during the first quarter worth approximately $159,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Oscar Health by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 215,650 shares of the company’s stock worth $2,827,000 after purchasing an additional 8,879 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Oscar Health by 7,473.3% in the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after purchasing an additional 2,242 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Oscar Health by 39.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,590 shares of the company’s stock valued at $6,169,000 after purchasing an additional 132,149 shares during the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on OSCR shares. Raymond James Financial raised Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research note on Thursday, February 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Oscar Health in a report on Tuesday, April 21st. Wall Street Zen raised Oscar Health from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. UBS Group reiterated a “neutral” rating and set a $15.00 price objective on shares of Oscar Health in a research report on Wednesday, February 11th. Finally, Wolfe Research initiated coverage on shares of Oscar Health in a research note on Tuesday. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Oscar Health currently has an average rating of “Hold” and an average target price of $16.78.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.